“The U.S. Food and Drug Administration approved Wegovy (semaglutide) injection (2.4 mg once weekly) for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), for use in addition to a reduced calorie diet and increased physical activity…The drug is indicated for chronic weight management in patients with a body mass index (BMI) of 27 kg/m2 or greater who have at least one weight-related ailment or in patients with a BMI of 30 kg/m2 or greater… The largest placebo-controlled trial enrolled adults without diabetes. Individuals who received Wegovy lost an average of 12.4% of their initial body weight compared to individuals who received placebo”
T Muniraj et al. Gastroenterol 2021; 160-1799-1808. Full text: AGA Clinical Practice Guidelines on Intragastric Balloons in the Management of Obesity
Related blog posts:
- Are We On the Verge of Pharmacologic Treatment of Obesity (Again)?
- Semaglutide: Potential or Problematic New Treatment for Fatty Liver Disease/NASH
- Should We Be Excited About a New Medication (Liraglutide) for Obesity?
- In the News: Weight Loss Intragastric Balloons
- FDA Warning for Obesity Intragastric Balloon Devices